review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Uri Kopylov | Q50913261 |
P2093 | author name string | Tal Engel | |
P2860 | cites work | Inflammatory Bowel Disease | Q22248115 |
Th17 plasticity and its changes associated with inflammatory bowel disease | Q26775934 | ||
Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease | Q26825174 | ||
Natalizumab for active Crohn's disease | Q28201431 | ||
Certolizumab pegol for the treatment of Crohn's disease | Q28236746 | ||
Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene | Q28270603 | ||
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial | Q28296771 | ||
Epidemiology and natural history of inflammatory bowel diseases | Q29619945 | ||
Increased expression of interleukin 17 in inflammatory bowel disease | Q29622829 | ||
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement | Q30620977 | ||
Biologics in inflammatory bowel disease: what are the data? | Q31017419 | ||
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. | Q33823950 | ||
Role of cytokines in the pathogenesis of inflammatory bowel disease | Q33896046 | ||
Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics | Q34141280 | ||
Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases | Q34181228 | ||
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial | Q34275637 | ||
Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 | ||
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 | ||
Review of the safety and efficacy of ustekinumab | Q34625984 | ||
Briakinumab for treatment of Crohn's disease: results of a randomized trial | Q35670615 | ||
Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease | Q35765082 | ||
Genetic origin of IBD. | Q35787625 | ||
Immune dysfunction in inflammatory bowel disease | Q36769500 | ||
Neuroimmunology of the gut: physiology, pathology, and pharmacology | Q37233795 | ||
Assessing response and loss of response to biological therapies in IBD. | Q37856191 | ||
Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis | Q37929165 | ||
The future of inflammatory bowel disease therapy: where do we go from here? | Q38072235 | ||
Ustekinumab: moving the target from psoriasis to Crohn's disease | Q38177321 | ||
Update on ustekinumab for the treatment of Crohn's disease | Q38238720 | ||
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience | Q39164487 | ||
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study | Q39869647 | ||
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. | Q40472089 | ||
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease | Q40503639 | ||
The IL-12/23/STAT Axis as a Therapeutic Target in Inflammatory Bowel Disease: Mechanisms and Evidence in Man. | Q40542750 | ||
Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases | Q41659087 | ||
Ustekinumab induction and maintenance therapy in refractory Crohn's disease | Q42514321 | ||
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. | Q42613896 | ||
Inflammatory bowel disease: etiology and pathogenesis | Q47899867 | ||
Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease | Q56992312 | ||
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up | Q85858615 | ||
Demyelination in a patient receiving ustekinumab for refractory Crohn's disease | Q87364504 | ||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Crohn's disease | Q1472 |
P304 | page(s) | 208-214 | |
P577 | publication date | 2016-07-06 | |
P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
P1476 | title | Ustekinumab in Crohn's disease: evidence to date and place in therapy | |
P478 | volume | 7 |
Q90579983 | A Single Center Experience With Long-Term Ustekinumab Use and Reinduction in Patients With Refractory Crohn Disease |
Q99707492 | An immune therapy model for effective treatment on inflammatory bowel disease |
Q48786898 | Diagnosis and management of inflammatory bowel disease in children. |
Q38735477 | Insights on the use of biosimilars in the treatment of inflammatory bowel disease |
Q50782815 | Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. |
Q47109861 | The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. |
Q39102244 | Update on the Use of Biologic Therapy in Ulcerative Colitis |
Search more.